This is a summary. To read the whole story subscribe to BostonGlobe.com
The pace of initial public offerings by Massachusetts biotechnology companies continues to pick up momentum, as a pair of Cambridge companies that previously filed to go public priced their shares this week.
Acceleron Pharma Inc., which is developing protein-based drugs to treat rare blood disorders, said Friday it will seek to raise about $65 million by offering 4.7 million shares to public investors at a price range of between $13 and $15 a share.
On Thursday, Bind Therapeutics Inc., which is developing programmable drugs to treat lung cancer and prostate cancer, indicated it plans to raise $71 million by selling 4.7 million shares at a range of $14 to $16.